OncoCyte
Oncocyte Enters $29.1M Securities Purchase Agreement
The company expects the funds to be sufficient to complete development of its IVD diagnostic transplant assay program.
Oncocyte Kidney Transplant Test Receives Expanded Medicare Coverage
The test can be used to monitor kidney transplant patients with newly developed donor-specific antibodies for antibody-mediated rejection.
In Brief This Week: Quest Diagnostics, T2 Biosystems, Oncocyte, Myriad Genetics, More
News items for the week of Nov. 11, 2024
Oncocyte Nets $10.2M in Private Placement, Notes New Customers for Transplant Test
The company intends to use the funds for general corporate purposes as it seeks to gain customers and regulatory support for its GraftAssure transplant rejection test.
Oncocyte Notified That It Lost, Regained Nasdaq Compliance
The issue arose with the death in April of a board member, who was also a member of Oncocyte's audit committee, and was resolved with a new appointment this month.
Jul 24, 2023
Oncocyte Initiates 1-for-20 Reverse Stock Split
Apr 13, 2023